$-1.17
(Market cap
$188,671 Mln
Revenue (TTM)
$37,238 Mln
P/E Ratio
24.3
P/B Ratio
20.5
Div. Yield
2.8 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
1 %
-
ROCE
11.9 %
-
Industry P/E
30.75
-
EV/EBITDA
14
-
Debt to Equity
5.6
-
Book Value
$--
-
EPS
$14.4
-
Face value
--
-
Shares outstanding
539,708,274
10 Years Aggregate
CFO
$97,559.00 Mln
EBITDA
$93,864.00 Mln
Net Profit
$64,460.00 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Amgen (AMGN)
| 5.3 | 3.9 | -6.8 | 18.7 | 16.0 | 7.8 | 8.1 |
|
BSE Sensex*
| -12.1 | -3.8 | -4.0 | -9.7 | 5.9 | 7.5 | 10.8 |
|
S&P 100
| 5.3 | -1.1 | 10.0 | 24.2 | 22.1 | 13.7 | 14.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Amgen (AMGN)
| 25.6 | -9.4 | 9.7 | 16.7 | 0.9 | -2.0 | 27.6 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Amgen (AMGN)
|
344.6 | 188,671.2 | 37,238.0 | 7,800.0 | 29.1 | 82.9 | 24.3 | 20.5 |
| 225.4 | 401,238.7 | 62,819.0 | 3,639.0 | 14.1 | -- | 110.8 | 50.5 | |
| 56.5 | 116,949.4 | 48,482.0 | 7,275.0 | 21.6 | 37.7 | 16 | 5.5 | |
| 1,144.7 | 1,003,449.8 | 72,249.5 | 25,275.0 | 43.6 | 91.9 | 40 | 30.4 | |
| 125.5 | 160,361.2 | 29,734.0 | 9,216.0 | 39.5 | 40.9 | 17.6 | 6.8 | |
| 237.0 | 549,254.7 | 96,362.0 | 21,040.0 | 20.2 | 26.2 | 26.5 | 6.6 | |
| 119.6 | 297,021.1 | 65,593.0 | 8,935.0 | 30.5 | 18.3 | 33.9 | 6.2 | |
| 149.1 | 283,857.3 | 56,053.0 | 13,533.8 | 30.3 | 32.7 | 21.3 | 7.1 | |
| 25.7 | 147,501.6 | 63,315.0 | 7,491.0 | 17.0 | 8.1 | 19.8 | 1.6 | |
| 44.7 | 107,767.5 | 47,354.0 | 7,555.0 | 19.6 | 10.3 | 19.6 | 1.3 |
Shareholding Pattern
View DetailsAbout Amgen (AMGN)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of... adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he Read more
-
Chairman, CEO & President
Mr. Robert A. Bradway
-
Chairman, CEO & President
Mr. Robert A. Bradway
-
Headquarters
Thousand Oaks, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Amgen (AMGN)
What is the current share price of Amgen Inc (AMGN) Today?
The share price of Amgen Inc (AMGN) is $344.57 (NASDAQ) as of 09-Jun-2026 16:22 EDT. Amgen Inc (AMGN) has given a return of 16% in the last 3 years.
What is the current PB & PE ratio of Amgen Inc (AMGN)?
The P/E ratio of Amgen Inc (AMGN) is 24.33 times as on 05-Jun-2026, a 21 discount to its peers’ median range of 30.75 times.
The P/B ratio of Amgen Inc (AMGN) is 20.53 times as on 05-Jun-2026, a 271 premium to its peers’ median range of 5.54 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
23.05
|
20.53
|
|
2024
|
34.54
|
24.04
|
|
2023
|
23.15
|
24.96
|
|
2022
|
21.61
|
38.67
|
|
2021
|
21.57
|
18.97
|
What is the 52 Week High and Low of Amgen Inc (AMGN)?
The 52-week high and low of Amgen Inc (AMGN) are Rs 391.29 and Rs 267.83 as of 10-Jun-2026.
What is the market cap of Amgen Inc (AMGN)?
Amgen Inc (AMGN) has a market capitalisation of $ 188,671 Mln as on 05-Jun-2026. As per SEBI classification, it is a Large Cap company.
Should I invest in Amgen Inc (AMGN)?
Before investing in Amgen Inc (AMGN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.